Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606539 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPK1HTTGPR35TSHR | |
| SCHEMBL3942261 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPK1HTTGPR35TSHR | |
| SCHEMBL761929 | 0.82 | SMN1; SMN2 (0.57) | ALDH1A1GPR35MAPTLMNASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL27652614 | 0.80 | ALDH1A1 (0.48) | ALDH1A1MAPK1HTTGPR35TSHR | |
| SCHEMBL8078061 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MAPK1HTTGPR35MAPT | |
| SCHEMBL742711 | 0.78 | CYP1A2 (0.43) | ALDH1A1GPR35MAPTLMNASMN1; SMN2 | |
| SCHEMBL5626986 | 0.78 | POLB (0.42) | ALDH1A1MAPK1GPR35MAPTAHR | |
| SCHEMBL5623763 | 0.78 | TSHR (0.52) | ALDH1A1MAPK1HTTGPR35MAPT | |
| SCHEMBL7878609 | 0.78 | SMN1; SMN2 (0.39) | ALDH1A1HTTGPR35MAPTLMNA | |
| SCHEMBL13223069 | 0.78 | SMN1; SMN2 (0.39) | ALDH1A1HTTGPR35MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107162960-B | The synthetic method of 2- pyridinemethanol | 安徽星宇化工有限公司 | 2019-10-22 | — | — | CN | claimed |
| CN-107162960-A | The synthetic method of 2 pyridinemethanols | 安徽星宇化工有限公司 | 2017-09-15 | — | — | CN | claimed |
| CN-107162960-B | The synthetic method of 2- pyridinemethanol | 安徽星宇化工有限公司 | 2019-10-22 | — | — | CN | disclosed |
| CN-107162960-B | The synthetic method of 2- pyridinemethanol | 安徽星宇化工有限公司 | 2019-10-22 | — | — | CN | disclosed |
| CN-107162960-A | The synthetic method of 2 pyridinemethanols | 安徽星宇化工有限公司 | 2017-09-15 | — | — | CN | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2017064675-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| EP-1831198-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006067445-A2 | CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067446-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | STS, TST, SCLY | ALDH1A1 143/4885MAPK1 3564/4885HTT 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.